Your browser doesn't support javascript.
loading
Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales.
Bhatnagar, Amelia; Ransom, Eric M; Machado, María-José; Boyd, Sandra; Reese, Natashia; Anderson, Karen; Lonsway, David; Elkins, Christopher A; Rasheed, J Kamile; Patel, Jean B; Karlsson, Maria; Brown, Allison C; Lutgring, Joseph D.
Afiliación
  • Bhatnagar A; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Ransom EM; Goldbelt C6, Juneau, AK, USA.
  • Machado MJ; Association of Public Health Laboratories, Silver Spring, MD, USA.
  • Boyd S; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Reese N; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Anderson K; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Lonsway D; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Elkins CA; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Rasheed JK; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Patel JB; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Karlsson M; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Brown AC; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
  • Lutgring JD; Division of Healthcare Quality Promotion, CDC, Atlanta, GA, USA.
J Antimicrob Chemother ; 76(4): 979-983, 2021 03 12.
Article en En | MEDLINE | ID: mdl-33367916
BACKGROUND: Aztreonam/avibactam is a combination agent that shows promise in treating infections caused by highly antibiotic-resistant MBL-producing Enterobacterales. This combination can be achieved by combining two FDA-approved drugs: ceftazidime/avibactam and aztreonam. It is unknown whether ceftazidime in the combination ceftazidime/aztreonam/avibactam has a synergistic or antagonistic effect on the in vitro activity of aztreonam/avibactam by significantly increasing or decreasing the MIC. OBJECTIVES: To determine whether increasing ceftazidime concentrations affect the MICs of aztreonam/avibactam alone. METHODS: A custom 8 × 8 chequerboard broth microdilution (BMD) panel was made using a digital dispenser (Hewlett-Packard, Corvallis, OR, USA). The panel included orthogonal 2-fold dilution series of aztreonam and ceftazidime ranging from 0.5 to 64 mg/L. Avibactam concentration was kept constant at 4 mg/L throughout the chequerboard. Thirty-seven Enterobacterales isolates from the CDC & FDA Antibiotic Resistance Isolate Bank or CDC's internal collection with intermediate or resistant interpretations to aztreonam and ceftazidime/avibactam were included for testing. All isolates harboured at least one of the following MBL genes: blaIMP, blaNDM or blaVIM. RESULTS: Regardless of the concentration of ceftazidime, aztreonam/avibactam with ceftazidime MICs for all 37 isolates were within one 2-fold doubling dilution of the aztreonam/avibactam MIC. CONCLUSIONS: Ceftazidime, in the combination ceftazidime/avibactam/aztreonam, did not affect the in vitro activity of aztreonam/avibactam in this sample of isolates. These findings can help assure clinical and public health laboratories that testing of aztreonam/avibactam by BMD can act as a reliable surrogate test when the combination of ceftazidime/avibactam and aztreonam is being considered for treatment of highly antibiotic-resistant MBL-producing Enterobacterales.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aztreonam / Ceftazidima Idioma: En Revista: J Antimicrob Chemother Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aztreonam / Ceftazidima Idioma: En Revista: J Antimicrob Chemother Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos